Physician profile
Robert Summerour
NPI 1811085160
$7,172.57
in general payments reported to CMS, 2019-2025
29 companies · $1,105 in 2025
The $1,105 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,658 · 2020: $746 · 2021: $1,399 · 2022: $1,432 · 2024: $832 · 2025: $1,105.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $734.84 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $715.74 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $654.70 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $637.84 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $601.02 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $505.24 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $478.80 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $462.18 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $308.44 | 2021-2025 | |
| Bausch Health US, LLC | $272.83 | 2019-2025 | Aplenzin |
| Allergan, INC. | $267.69 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $254.10 | 2019-2025 | Hetlioz, Fanapt |
| Lundbeck LLC | $161.79 | 2019-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $152.25 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $127.77 | 2019-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $127.48 | 2021-2022 | |
| Indivior INC. | $103.81 | 2019-2020 | |
| Corium, LLC | $92.34 | 2021-2024 | Azstarys |
| Adlon Therapeutics L.P. | $84.90 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $67.83 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $65.11 | 2020-2022 | |
| Eisai INC. | $59.94 | 2020-2021 | |
| Noven Therapeutics, LLC | $55.51 | 2020-2022 | |
| Almatica Pharma LLC | $53.72 | 2024-2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $45.12 | 2024-2025 | Cobenfy |
| Arbor Pharmaceuticals, INC. | $27.00 | 2019-2020 | |
| Alfasigma USA, INC. | $20.28 | 2022 | |
| Owp Pharmaceuticals, INC. | $19.02 | 2022 | |
| Neuronetics, INC. | $15.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Summerour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.